Aberrant glycosylation associated with enzymes as cancer biomarkers
2011
Cancer Biomarkers and Aberrant Glycosylation
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Danni L Meany, Daniel W Chan
Primary Institution: Johns Hopkins University
Hypothesis
Can aberrant glycosylation of enzymes be used as cancer biomarkers?
Conclusion
Aberrant glycosylation can improve the specificity of existing cancer biomarkers and aid in the discovery of new ones.
Supporting Evidence
- Enzymes like glycosyltransferases can serve as cancer biomarkers.
- Specific glycoforms of existing biomarkers can improve their cancer specificity.
- Technological advancements in glycomic and glycoproteomic approaches provide new opportunities for biomarker discovery.
Takeaway
This study talks about how changes in sugars on proteins can help doctors find cancer better and make treatments more personal.
Methodology
The review discusses various glycomic and glycoproteomic technologies used to identify cancer biomarkers.
Potential Biases
Potential bias in the selection of studies reviewed.
Limitations
The review is based on existing literature and may not include all recent findings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website